Tucows Inc (NASDAQ:TCX) Q1 2024 Earnings Call Transcript insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.
PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and.
Verona Pharma To Present Additional Analyses Of Positive Phase 3 ENHANCE Studies In COPD At ATS 2024 menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
EpiEndo Pharmaceuticals: EpiEndo reports Phase 2A results for lead asset, EP395, in COPD finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
REYKJAVIK, Iceland, April 10, 2024 EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, announces the successful completion of its Phase 2A clinical trial for EP395 in patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD).